The majority of MBC cases are ER and PR positive (90.8% and 83%, respectively), HER2 and Ki67/MIB1 negative (84.2% and 61.7%, respectively) and have intermediate/moderate tumor grade (G2) (52.4%). This evidence concerns the gene MKI67 and neoplasm.